The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years.

This month’s focus on pharmaphorum is clinical trials, so who better to share their view on global clinical trials than Zheng Su, Editor-in-Chief of the Contemporary Clinical Trials journal ...